The Coca-Cola Co K vs Revvity Inc — how do they compare? The Coca-Cola Co K trades at $88.09 (market cap $377.63B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: The Coca-Cola Co K is far larger — about 22.2× Revvity Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.42%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Revvity Inc for 12 Days on average.
| KO | RVTY | |
|---|---|---|
Market Cap | $377.63B | $16.98B |
Volume | 14,894,568 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $157.36 |
52-Week Low | $66.37 | $82.26 |
Typical Hold Time | 154 Days | 12 Days |
Enterprise Value | $404.81B | $19.30B |
Dividend Yield | 2.42% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.
KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →